Craig Zwickl
Overview
Explore the profile of Craig Zwickl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bassan A, Alves V, Amberg A, Anger L, Beilke L, Bender A, et al.
Comput Toxicol
. 2022 Jun;
20.
PMID: 35721273
The kidneys, heart and lungs are vital organ systems evaluated as part of acute or chronic toxicity assessments. New methodologies are being developed to predict these adverse effects based on...
2.
Johnson C, Anger L, Benigni R, Bower D, Bringezu F, Crofton K, et al.
Comput Toxicol
. 2022 Apr;
21.
PMID: 35368849
Understanding the reliability and relevance of a toxicological assessment is important for gauging the overall confidence and communicating the degree of uncertainty related to it. The process involved in assessing...
3.
Bassan A, Alves V, Amberg A, Anger L, Auerbach S, Beilke L, et al.
Comput Toxicol
. 2022 Mar;
20.
PMID: 35340402
Hepatotoxicity is one of the most frequently observed adverse effects resulting from exposure to a xenobiotic. For example, in pharmaceutical research and development it is one of the major reasons...
4.
Johnson C, Ahlberg E, Anger L, Beilke L, Benigni R, Bercu J, et al.
Regul Toxicol Pharmacol
. 2020 Jul;
116:104688.
PMID: 32621976
The assessment of skin sensitization has evolved over the past few years to include in vitro assessments of key events along the adverse outcome pathway and opportunistically capitalize on the...
5.
Hasselgren C, Ahlberg E, Akahori Y, Amberg A, Anger L, Atienzar F, et al.
Regul Toxicol Pharmacol
. 2019 Jun;
107:104403.
PMID: 31195068
In silico toxicology (IST) approaches to rapidly assess chemical hazard, and usage of such methods is increasing in all applications but especially for regulatory submissions, such as for assessing chemicals...
6.
Myatt G, Ahlberg E, Akahori Y, Allen D, Amberg A, Anger L, et al.
Regul Toxicol Pharmacol
. 2018 Apr;
96:1-17.
PMID: 29678766
The present publication surveys several applications of in silico (i.e., computational) toxicology approaches across different industries and institutions. It highlights the need to develop standardized protocols when conducting toxicity-related predictions....
7.
Ahlberg E, Amberg A, Beilke L, Bower D, Cross K, Custer L, et al.
Regul Toxicol Pharmacol
. 2016 Feb;
77:1-12.
PMID: 26879463
Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in...
8.
Jolly R, Riaz Ahmed K, Zwickl C, Watson I, Gombar V
Regul Toxicol Pharmacol
. 2015 Feb;
71(3):388-97.
PMID: 25656493
The evaluation of impurities for genotoxicity using in silico models are commonplace and have become accepted by regulatory agencies. Recently, the ICH M7 Step 4 guidance was published and requires...
9.
Fostel J, Burgoon L, Zwickl C, Lord P, Corton J, Bushel P, et al.
Toxicol Sci
. 2007 Apr;
99(1):26-34.
PMID: 17442663
Data from toxicology and toxicogenomics studies are valuable, and can be combined for meta-analysis using public data repositories such as Chemical Effects in Biological Systems Knowledgebase, ArrayExpress, and Gene Expression...
10.
Fostel J, Choi D, Zwickl C, Morrison N, Rashid A, Hasan A, et al.
Toxicol Sci
. 2005 Sep;
88(2):585-601.
PMID: 16150882
A critical component in the design of the Chemical Effects in Biological Systems (CEBS) Knowledgebase is a strategy to capture toxicogenomics study protocols and the toxicity endpoint data (clinical pathology...